← All trials
NCT06034470
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 13, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Sep 13, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- ImmunogenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.